ClinicalTrials.gg
RecruitingNCT05462704IVIDA2Updated Jun 10, 2025

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

A Phase 3 interventional study of Ferric derisomaltose and Ferrous sulfate in Iron Deficiency Anemia and Pregnancy, sponsored by Women and Infants Hospital of Rhode Island. Recruiting at 8 sites in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-06-10.

Sponsored by Women and Infants Hospital of Rhode Island · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 8 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Planned enrollment
8th of 32
300 · median 121
Started
2023
with 2 others
Phase 3
18 of 32
4 open now
Registered
25th of 32
by date

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 8th largest by planned enrollment, is one of 3 that started in 2023, is one of 18 in phase 3, and was the 25th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

8 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment.

Read the detailed description

Iron-deficiency anemia (IDA) is a common, undertreated problem in pregnancy. According to data from the U.S. National Health and Nutrition Examination Survey (NHANES), 25% of pregnant women in the U.S. have iron deficiency, with rates of 7%, 24%, and 39% in the first, second, and third trimesters, respectively. The prevalence of IDA is estimated at 16.2% overall and up to 30% at delivery. Iron deficiency is associated with significant adverse maternal and fetal outcomes including blood transfusion, cesarean delivery, depression, preterm birth, and low birth weight. Moreover, iron-deficient mothers are at risk of delivering iron-deficient neonates who, despite iron repletion, remain at risk for delayed growth and development. While treatment with iron supplementation is recommended during pregnancy, questions remain about the optimal route of delivery. Oral iron therapy, the current standard, is often suboptimal: up to 70% of patients experience significant gastrointestinal side effects (nausea, constipation, diarrhea, indigestion, and metallic taste) that prevent adherence to treatment, resulting in persistent anemia. Intravenous (IV) iron is an attractive alternative because it mitigates the adherence and absorption challenges of oral iron. However, IV iron costs more, and there are historical concerns about adverse reactions.

The American College of Obstetricians and Gynecologists (ACOG) recommends oral iron for the treatment of IDA in pregnancy, with IV iron reserved for the restricted group of patients. Our preliminary data show that this approach leads to 30% of patients with persistent IDA at delivery and an associated 3 to 6-fold increased risk of peripartum blood transfusion. ACOG's preferential recommendation of oral iron is based on paucity of data on the benefits and safety of IV iron, compared with oral iron, in pregnancy. Our published systematic review and meta-analysis showed that IV iron is associated with greater increase in maternal hemoglobin (Hb), but most of the primary trials were conducted in developing countries, included small sample sizes (50 - 252), and did not assess meaningful maternal and neonatal outcomes. The current Cochrane review noted that despite the high incidence and disease burden associated with IDA in pregnancy, there is paucity of quality trials assessing clinical maternal and neonatal effects of iron administration in women with anemia. The authors called for "large, good quality trials assessing clinical outcomes." The only large randomized trial of IV versus oral iron, conducted in India, showed no difference in a maternal composite outcome, but it is limited by use of iron sucrose which required five infusions, resulting in a wide range of iron doses (200 - 1600 mg). In addition, the primary composite outcome included some components not directly related to anemia. In contrast, our pilot trial of a single infusion of 1000 mg of IV low molecular weight iron dextran in pregnant women in the U.S. with moderate-to-severe IDA significantly reduced the rate of maternal anemia at delivery and showed promise for improving maternal morbidity by reducing rates of blood transfusion.

This is the first definitive double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<30 ng/mL) at 13 - 30 weeks will be effective, safe and cost-effective in reducing severe maternal morbidity-as measured by maternal anemia at delivery-and will also improve offspring neurodevelopment. A multidisciplinary team of investigators in the U.S., will pursue the following specific aims:

Primary Aim: Evaluate the effectiveness and safety of IV iron, compared with oral iron, in reducing the rate of anemia at delivery in pregnant women with IDA.

Secondary Aim 1: Estimate the cost-effectiveness of IV iron , compared with oral iron, in pregnant women with IDA as measured by incremental cost per Quality Adjusted Life-year (QALY).

Secondary Aim 2: Assess the effect of IV iron, compared with oral iron, on offspring brain myelin content and neurodevelopment.

03

Conditions studied

  • Iron Deficiency Anemia
  • Pregnancy
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women between the ages of 18-45
  • Singleton gestation
  • Iron-deficiency anemia (serum ferritin \<30ng/mL and \<11 g/dL)
  • At 13-30 weeks gestation
  • Plan to deliver at participating hospital

Exclusion criteria

Exclusion Criteria:

  • Non-iron-deficiency anemia e.g thalassemia, sickle cell disease, B12 or folate deficiency, hypersplenism.
  • Malabsorptive syndrome, inflammatory bowel disease, gastric bypass, or sensitivity to oral or IV iron
  • Multiple gestation
  • Inability or unwillingness to provide
  • Inability to communicate with members of the study team, despite the presence of an interpreter
  • Planned delivery at a non-study affiliated hospital
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    IV Iron

    Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes and daily placebo tablets until delivery.

    Drug: Ferric derisomaltose

  • Active comparator
    Oral Iron

    Participants assigned to the oral iron group will receive a single 250 mL IV normal saline infusion given over 20 minutes and 325mg tablets of ferrous sulfate (65 mg of elemental iron) to be taken until delivery.

    Drug: Ferrous sulfate

Interventions

  • DrugIron isomaltoside 1000Studies of Iron isomaltoside 1000Iron isomaltoside 1000 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants assigned to the IV iron group will receive a single IV infusion of 1000 mg ferric derisomaltose (Monoferric, Pharmacosmos Therapeutics Inc., Morristown, NJ) in 250 mL given over 20 minutes.

    Also known as: Monoferric

  • 325mg ferrous sulfate tablets (65 mg of elemental iron), 1 to 3 orally per day.

    Also known as: Ferosul

06

What researchers measure

Primary outcomes

  1. Rate of maternal anemia (hgb<11mg/dL) at delivery

    Hemoglobin \<11mg/dL on admission to inpatient obstetrics unit for labor and delivery

    Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant

Secondary outcomes

  1. Concentration of maternal hemoglobin at delivery

    Hemoglobin on admission to inpatient obstetrics unit for labor and delivery

    Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant

  2. Rate of maternal blood transfusion at delivery

    Maternal blood transfusion from delivery to 7 days postpartum

    Time frame: Delivery to 7 days postpartum

  3. Concentration of maternal ferritin at delivery

    Maternal ferritin on admission to inpatient obstetrics unit for labor and delivery

    Time frame: Within 24 hours of admission to inpatient obstetrics unit for delivery of infant

  4. Concentration of maternal hemoglobin postpartum day 1

    Maternal hemoglobin on postpartum day 1

    Time frame: On day after participant delivered her infant; postpartum day 1

  5. Rate of cesarean delivery

    Cesarean delivery for any indication in patients without prior cesarean deliveries

    Time frame: Once at infant delivery

  6. Rate of severe infusion adverse events

    Safety and tolerability

    Time frame: 2 days after intravenous iron or placebo infusion

  7. Rate of mild medication adverse events

    Safety and tolerability

    Time frame: 4 weeks after initiation of oral iron or placebo

  8. Edinburgh Perinatal Depression Scale score

    Edinburgh Perinatal Depression Scale score. Minimum score 0, maximum score 30, higher scores indicate worse depressive symptoms.

    Time frame: At randomization (baseline) and at 4-6 weeks postpartum

  9. Maternal EuroQol Group Quality-of-Life Questionnaire score

    Maternal EuroQol Group Quality-of-Life Questionnaire (EQ-5D-5L). Minimum score 11111 (full health), maximum score 55555 (worst health), higher scores indicate worse quality of life.

    Time frame: At 6 weeks postpartum by phone or in person

  10. Rate of Maternal infection

    Any infection diagnosed from initiation of treatment until 6 weeks postpartum

    Time frame: From initiation of treatment until 6 weeks postpartum

  11. Rate of Composite Maternal Complications

    Maternal mortality or any one of several maternal morbidities

    Time frame: At 6 weeks postpartum

  12. Gestational age at delivery

    Gestational age at delivery

    Time frame: At delivery

  13. Rate of preterm birth at less then 37 weeks

    Preterm birth; gestational age at delivery at less than 37 weeks (spontaneous or indicated)

    Time frame: At delivery

  14. Rate of Neonatal Intensive Care Unit Admission

    Admission to the neonatal intensive care unit for any indication

    Time frame: At birth through through 30 days from birth

  15. Neonatal birth weight

    Infant birth weight

    Time frame: At birth

  16. Concentration of umbilical artery pH

    Concentration of umbilical artery pH from umbilical cord gases from infant umbilical cord segment at birth

    Time frame: At birth

  17. Concentration of umbilical artery bicarbonate

    Concentration of umbilical artery bicarbonate from umbilical cord gases from infant umbilical cord segment at birth

    Time frame: At birth

  18. Concentration of umbilical artery base excess

    Concentration of base excess from umbilical cord gases from infant umbilical cord segment at birth

    Time frame: At birth

  19. Concentration of umbilical artery lactate

    Concentration of umbilical artery lactate from umbilical cord gases from infant umbilical cord segment at birth

    Time frame: At birth

  20. Concentration of neonatal hemoglobin

    Concentration of neonatal hemoglobin from umbilical cord blood at birth or first neonatal complete blood count

    Time frame: At birth

  21. Concentration of neonatal ferritin

    Concentration of neonatal ferritin from umbilical cord blood at birth or first neonatal blood draw

    Time frame: At birth

  22. Neonatal Apgar scores

    Apgar scores at 1 and 5 minutes of life. Minimum score 0, maximum score 10, higher scores indicate better well being.

    Time frame: At 1 minute and 5 minutes of life

  23. Rate of composite neonatal complication

    Neonatal mortality or any one of several neonatal morbidities

    Time frame: Through 30 days from birth

  24. Concentration of child brain myelin

    Concentration of infant brain myelin from magnetic resonance imaging

    Time frame: At an average of 6 months and 36 months

  25. Child Mullen Scale of Early Learning Score

    Mullen Scale of Early Learning Score as percentile. Minimum score 1, maximum score 99, higher scores indicate better neurodevelopment.

    Time frame: At an average of 6 months and 36 months

07

Study locations

8 of 8 sites recruiting
  • University of Alabama Medical Center
    Birmingham, Alabama 35401, United States
    Recruiting
    • Carolyn Webster, MD · Contact
  • GNP Research at Heme-on-Call
    Miami, Florida 33143, United States
    Recruiting
    • Steven Fein, MD · Contact
  • Michigan University Medical Center
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Molly Stout, MD, MSCI · Contact
  • Washington University Medical Center
    Saint Louis, Missouri 65105, United States
    Recruiting
    • Ebony Carter, MD, MPH · Contact
  • Oregon Health and Sciences Uiversity Medical Center
    Portland, Oregon 97239, United States
    Recruiting
    • Ashley Benson, MD · Contact
  • Hasbro Children's Hospital
    Providence, Rhode Island 02905, United States
    Recruiting
    • Viren D'sa, MD · Contact
  • Women & Infants Hospital of Rhode Island
    Providence, Rhode Island 02905, United States
    Recruiting
    • Methodius Tuuli, MD, MPH, MBA · Contact
  • University of Utah Hospital
    Salt Lake City, Utah 84132, United States
    Recruiting
    • Ann Bruno, MD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Data will be collected from human subjects and will be shared according to NIH guidelines. The investigators are committed to the sharing of final data, being mindful that the rights and privacy of people who participate in research must be protected at all times. The investigators will make a complete study dataset available for sharing. The investigators will have a description of study dataset, including code books, meta-data related to the dataset, and documented programming code used for creating the final study population, for creating variables, and for conducting all outcomes analyses. The investigators will remain HIPAA compliant, and therefore any datasets resulting from participants will be free of any identifiers that would permit linkages to individual research participants and variables that could lead to deductive disclosure of individual subjects.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 5 years after completion of study

Access criteria: The investigators will make the data and associated documentation available to users under a data-sharing agreement that provides for commitment to: a) using the data only for research purposes and not to identify any individual participant; b) securing the data using appropriate computer technology; and c) destroying or returning the data after analyses are completed. Timelines for distribution of data will vary depending on any required restrictions as mentioned above. Data may be distributed by a number of electronic methods, including web-based databases, datasets, and spreadsheets, or via electronic media such as compact discs.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Mar 2027, 50 months after the start.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 50 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2022
First posted
Jul 18, 2022
StartActual
Jan 17, 2023
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05462704
Lead sponsor
Women and Infants Hospital of Rhode Island
Responsible party
Methodius Tuuli (Professor and Chair of Obstetrics and Gynecology, Women and Infants Hospital of Rhode Island) — Principal investigator
First posted
Jul 18, 2022
Start date
Jan 17, 2023
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 10, 2025

Study contacts

Crystal Ware, BSN, CCRP
Contact
cware@wihri.org
401-274-1122
Methodius Tuuli, MD, MPH, MBA
principal investigator · Women and Infants Hospital of Rhode Island

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion